CliffBio
small molecule

BELEODAQ

BELINOSTAT

Loss of exclusivityOctober 2027latest FDA-listed patent expiry
CompanyAcrotech Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameBELEODAQ
Active ingredientBELINOSTAT
Strength500MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2014
Marketing statusRX

Listed patents

PatentExpiresType
8835501October 2027product
6888027August 2026substance, product

More from Acrotech Biopharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found